

WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or a pharmacologically acceptable salt thereof, and an HMG-CoA reductase inhibitor.

2. The pharmaceutical composition according to claim 1 wherein the HMG-CoA reductase inhibitor is Pravastatin, Lovastatin, Simvastatin, Fluvastatin, Rivastatin, Atorvastatin, Rosuvastatin or Pitavastatin.

3. The pharmaceutical composition according to claim 1 wherein the HMG-CoA reductase inhibitor is Pravastatin, Lovastatin, Simvastatin, Fluvastatin, Atorvastatin, Rosuvastatin or Pitavastatin.

4. The pharmaceutical composition according to claim 1 wherein the HMG-CoA reductase inhibitor is Pravastatin, Atorvastatin or Pitavastatin.

5. The pharmaceutical composition according to claim 1 wherein the HMG-CoA reductase inhibitor is Pitavastatin or Atorvastatin.

6. The pharmaceutical composition according to claim 1 wherein the HMG-CoA reductase inhibitor is Pravastatin.

7. The pharmaceutical composition according to claim 6 wherein the HMG-CoA reductase inhibitor is Atorvastatin.

0099443712-083101  
101220-274650

8. The pharmaceutical composition comprising N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate, and a HMG-CoA reductase inhibitor.

9. The pharmaceutical composition according to claim 8 wherein the HMG-CoA reductase inhibitor is Pravastatin, Lovastatin, Simvastatin, Fluvastatin, Rivastatin, Atorvastatin, Rosuvastatin or Pitavastatin.

10. The pharmaceutical composition according to claim 8 wherein the HMG-CoA reductase inhibitor is Pravastatin, Lovastatin, Simvastatin, Fluvastatin, Atorvastatin, Rosuvastatin or Pitavastatin.

11. The pharmaceutical composition according to claim 8 wherein the HMG-CoA reductase inhibitor is Pravastatin, Atorvastatin or Pitavastatin.

12. The pharmaceutical composition according to claim 8 wherein the HMG-CoA reductase inhibitor is Pravastatin or Atorvastatin.

13. The pharmaceutical composition according to claim 8 wherein the HMG-CoA reductase inhibitor is Pravastatin.

14. The pharmaceutical composition according to claim 8 wherein the HMG-CoA reductase inhibitor is Atorvastatin.

15. A method of prevention or treatment of atherosclerosis or xanthoma comprising administering to a human patient in need thereof, an effective amount of a combination of agents comprising N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or a pharmacologically acceptable salt thereof, and an HMG-CoA reductase inhibitor.

16. The method according to claim 15 wherein the HMG-CoA reductase inhibitor is Pravastatin, Lovastatin, Simvastatin, Fluvastatin, Rivastatin, Atorvastatin, Rosuvastatin or Pitavastatin.

17. The method according to claim 15 wherein the HMG-CoA reductase inhibitor is Pravastatin, Lovastatin, Simvastatin, Fluvastatin, Atorvastatin, Rosuvastatin or Pitavastatin.

18. The method according to claim 15 wherein the HMG-CoA reductase inhibitor is Pravastatin, Atorvastatin or Pitavastatin.

19. The method according to claim 15 wherein the HMG-CoA reductase inhibitor is Pravastatin or Atorvastatin.

20. The method of claim 15 wherein the HMG-CoA reductase inhibitor is Pravastatin.

21. The method according to claim 15 wherein the HMG-CoA reductase inhibitor is Atorvastatin.

22. A method of prevention or treatment of atherosclerosis or xanthoma comprising administering to a human patient in need thereof, an effective amount of a combination of agents comprising N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate, and a HMG-CoA reductase inhibitor.

23. The method according to claim 22 wherein the HMG-CoA reductase inhibitor is Pravastatin, Lovastatin, Simvastatin, Fluvastatin, Rivastatin, Atorvastatin, Rosuvastatin or Pitavastatin.

24. The method according to claim 22 wherein the HMG-CoA reductase inhibitor is Pravastatin, Lovastatin, Simvastatin, Fluvastatin Atorvastatin, Rosuvastatin or Pitavastatin.

25. The method according to claim 22 wherein the HMG-CoA reductase inhibitor is Pravastatin, Atorvastatin or Pitavastatin.

26. The method according to claim 22 wherein the HMG-CoA reductase inhibitor is Pravastatin or Atorvastatin.

27. The method according to claim 22 wherein the HMG-CoA reductase inhibitor is Pravastatin.

28. The method according to claim 22 wherein the HMG-CoA reductase inhibitor is Atorvastatin.